TEVA BUYS IVAX IN $7.4 BILLION DEAL

Teva Pharmaceutical Industries Ltd. agreed to buy Ivax Corp. of the U.S. Monday in a $7.4 billion cash-and-stock deal that will restore the Israeli company's No. 1 position in the market for generic medicines. Teva said it will pay either $26 cash or 0.8741 Teva American Depositary Receipts for each share of Ivax, giving shareholders of the Miami drug maker about a 15% stake in the combined company. The agreement stipulates that no more than half of the total acquisition price be paid in cash.

Wall Street Journal (http://online.wsj.com/article/0,,SB112228460343494771,00.html?mod=health%5Fhome%5Fstories)